Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura: Final Appraisal Document

In DRAFT guidance, NICE recommends caplacizumab with plasma exchange and immunosuppression as an option for treating an acute episode of acquired thrombotic thrombocytopenic purpura in adults, and in young people aged ≥12 years who weigh ≥40 kg.

Source:

National Institute for Health and Care Excellence